Human Clinical Trials
We're actively engaged with the USA FDA on our Pre-Submission Investigational Device Exemption for RadioGel™. Once the completed application is finalized, and submited;
upon approval we're planning to begin by treating thyroid cancer lymph nodes.
RadioGel™ is a precision radionuclide therapy device for delivering therapeutic radiation into solid metastatic tumors in the lymph nodes associated with papillary thyroid cancer
which are accessible by percutaneous direct needle injection in patients who are not surgical candidates or who have declined surgery.